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Abstract
HBV vaccine was introduced into the Expanded Programme on Immunization (EPI) in Senegal and Cameroon in 2005. We
conducted a cross-sectional study in both countries to assess the HBV immune protection among children. All consecutive
children under 4 years old, hospitalized for any reason between May 2009 and May 2010, with an immunisation card and a
complete HBV vaccination, were tested for anti-HBs and anti-HBc. A total of 242 anti-HBc-negative children (128 in
Cameroon and 114 in Senegal) were considered in the analysis. The prevalence of children with anti-HBs $10 IU/L was
higher in Cameroon with 92% (95% CI: 87%–97%) compared to Senegal with 58% (95% CI: 49%–67%), (p,0.001). The
response to vaccination in Senegal was lower in 2006–2007 (43%) than in 2008–2009 (65%), (p=0.028). Our results,
although not based on a representative sample of Senegalese or Cameroonian child populations, reveal a significant
problem in vaccine response in Senegal. This response problem extends well beyond hepatitis B: the same children who
have not developed an immune response to the HBV vaccine are also at risk for diphtheria, tetanus, pertussis (DTwP) and
Haemophilus influenzae type b (Hib). Field biological monitoring should be carried out regularly in resource-poor countries
to check quality of the vaccine administered.
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Introduction
The prevalence of HBV chronic infection is particularly high in
Sub Saharan Africa, ranging from 7 to 26% [1]. Because available
treatment for hepatitis B virus infection does not provide a
complete cure and is very costly in developing countries,
prevention remains crucial [2]. Previous studies have demonstrat-
ed immunogenicity of HBV vaccine ranging between 88% and
94% with anti-HBs response $10 mUI/ml, associated (pentava-
lent vaccine) or not with diphtheria-tetanus-pertussis (DTwP) and
Haemophilus influenzae type b (Hib) [3,4,5,6]. In 1991, the World
Health Organization recommended that all countries introduce
hepatitis B vaccination into their routine national infant immu-
nisation programmes [7].
In Senegal, previous studies have demonstrated an HBV
chronic infection prevalence of 17% among blood donors [8], a
prevalence of HBV exposure of 60% among children between 0
and 5 years old [9], and 14 % of HBsAg positivity among
pregnant women [10]. In Cameroon, the prevalence of HBsAg
varies from 12% among Pygmies [11] to 20% among children of
primary school age [12] and 25 % among a population older than
4 years of age [13]. In response to WHO recommendations,
Cameroon and Senegal integrated the HBV vaccination into the
Expanded Programme on Immunization (EPI) in 2005. The
DTwP-HBV-Hib combination vaccine Zilbrix
TM developed by
GSK is currently used by the National Programme of Cameroon,
while Quinvaxem
TM, a DTwP-HBV-Hib vaccine co-developed by
Crucell and Novartis, is administrated in Senegal. Both combina-
tion vaccines have been shown to be immunogenic and well
tolerated [5,14]. The three doses of the pentavalent vaccine are
administrated at 6, 10 and 14 weeks of age in both countries,
according to WHO recommendations. With the introduction and
expansion of the HBV vaccine in sub-Saharan Africa, it remains
imperative to monitor the seroprotective response to HBV
childhood immunisation programmes.
We conducted a cross-sectional study in Senegal and Cameroon
in order to assess the response to vaccination among children with
a complete HBV vaccination.
Results
A total of 242 children with an immunisation card were
recruited, 128 in Cameroon, and 114 in Senegal (Table 1). Forty-
seven percent of children were female, and the overall median age
was 15 months [9;21]. Senegal presented a higher prevalence of
children suffering from moderate or severe malnutrition (66%),
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children’s hospitalization were gastro-intestinal infections and
infectious syndromes in Cameroon (60%), and gastro-intestinal
infections and respiratory diseases in Senegal (60%). The median
[IQR] delays between the first and the second dose of the HBV
vaccination and between the second and the third dose were
30 days [28; 35] and 31 days [28; 35] in Cameroon, and 32 days
[30; 35] and 33 days [31; 36] in Senegal, respectively. The
prevalence of children with anti-HBs $10 IU/L was higher in
Cameroon, with 92% (95% CI: 87%–97%) compared to Senegal,
with 58% (95% CI: 49%–67%), (p,0.001). The proportion of
children with anti-HBs $100 IU/L was 66% and 23% in
Cameroon and Senegal, respectively (p,0.001) (Table 1).
In the two countries, the children were recruited in two hospitals
and no differences were revealed in the percentages of responders.
The Cameroon hospitals showed 95% (Essos Hospital) versus 87%
(Chantal Biya Foundation) responding (p=0.17), whereas the
Senegal hospitals indicated 56% (Albert Royer Paediatric Hospi-
tal) versus 65% (Ho ˆpital Principal) responding (p=0.48) (data not
shown).
Taking into account the year of vaccination, we found that in
Senegal, the response to vaccination was lower in 2006–2007
(43%), compared with 2008–2009 (65%), (p=0.028).
In contrast, in Cameroon, no difference existed between the
prevalence of children anti-HBs+ during these two time periods
(96% versus 91%, p=0.69) (Figure 1).
Nutritional status was significantly correlated with response to
the HBV vaccination (p,0.001), with 85% of children protected
(anti-HBs $10 IU/L) among those with normal nutrition status
versus 60 % of children with moderate to severe malnutrition. The
percentages of protected children were lower in the two countries
among the children with moderate or severe malnutrition (12% vs
20% in Cameroon, 62% vs 71% in Senegal). However, the
nutritional status was not significant when adjusted for the country
of residence (Table 2).
Discussion
Overall, we note that the immunization schedule was well
respected for all children in both countries, with a median time
between doses close to 30 days.
While we observed in Cameroon a protection rate of 92%,
corresponding with previously reported protection rates for
hepatitis B vaccination in both developing and developed
countries [3,4,5], we were surprised by the low protection level
(58%) in Senegal. Moreover, in Senegal, the proportion of
children responding to the vaccine varied dramatically over time
with a low protected rate in 2006–2007 (43%).
Table 1. Characteristics of the children.
Variables Cameroon N=128 Senegal N=114 Total N=242 p
Sex, female N (%) 55(43) 59 (52) 114 (47) 0.17
Age (months)* 13 [9;20] 17 [11; 24] 15 [9;21] 0.004
Moderate or severe malnutrition
(WAZ-score #22)N(%)
15 (12) 75 (66) 90 (38) ,0.001
Reasons for hospitalisation N( % ) ,0.001
Gastro-intestinal infection 34 (27) 33 (29) 67 (28)
Respiratory Infection 19 (15) 35 (31) 54 (22)
Malaria 16 (13) 2 (2) 18 (7)
Other Infectious Syndrome 42 (33) 13 (11) 55 (23)
Other reasons (convulsions, anaemia, malnutrition) 17 (13) 31 (27) 48 (20)
Delay of the HBV vaccination (days)*
Between the first and the second dose 30 [28; 35] 32 [30; 35] 32 [28;35] 0.001
Between the second and the third dose 31 [28; 35] 33 [31; 36] 32 [29; 35] 0.008
Anti-HBs N( % )
$10 IU/L 118 (92) 66 (58) 184 (76) ,0.001
$100 IU/L 85 (66) 26 (23) 111 (46) ,0.001
*Median [Q1; Q3].
doi:10.1371/journal.pone.0038153.t001
Figure 1. Immune response (anti-HBs levels) to complete HBV
vaccination according to the year of vaccination in Cameroon
and Senegal among children with immunization card.
doi:10.1371/journal.pone.0038153.g001
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hypothesis of lower vaccine immunogenicity, by measuring the
response to the diphtheria antigens associated in the same vial.
Antibodies against diphtheria antigens persist several months
after vaccination [15]. In the present study, the detection of
antibodies was performed using EIA (IgG testkit, Genzyme,
Germany) in nineteen blood samples from Senegalese children
vaccinated less than one year after vaccination: nine responder
children (anti-HBs+) and ten vaccinated and non-responder
children (anti-HBs–). Low anti-diphtheria antibody response was
significantly associated with the lack of anti-HBs antibodies
(p=0.036), but the low value of correlation (r=0.48) impaired
any definitive conclusion. The low value of the coefficient
between anti-diphtheria and anti-HBs antibodies is probably due
to the small number of cases.
Several possible explanations may account for these results.
First, there may exist problems with storage conditions in Senegal,
since frequent power outages may provoke lapses in backup
electrical systems and compromise the cold chain [16]. Second,
there may be a quality problem with the pentavalent Quinvax-
em
TM (Crucell) vaccine. In 2011, for instance, Quinvaxem
production temporarily ceased because of sterilisation problems
[17]. A third explanation may be related to children’s nutritional
status, which is much more severe among Senegalese children
than among Cameroonian children. The small number of children
with moderate or severe malnutrition in our study, especially in
Cameroon, led to the result that when both variables (nutritional
status and country) were introduced simultaneously in a multi-
variate model, only country remained significantly associated with
antibody response. However, the percentages of protected children
were lower in the two countries among those children with
moderate or severe malnutrition. These results are in accordance
with recent studies that reported no immune response difference
between healthy children and those with compromised nutritional
status [18,19,20,21].
Although we cannot definitively explain the reason(s) for anti-
HBV vaccination failure in Senegal, the striking disparity between
our results, based on anti-HBs antibody levels, and vaccination
card registrations demonstrates a critical need for monitoring
accurately vaccine delivery and coverage. Current vaccination
coverage surveys are based mainly on an assessment of immuni-
sation cards [22]. Yet our results, although not based on a
representative sample of Senegalese or Cameroonian child
populations, reveal a significant problem in vaccine response in
Senegal that present official surveys cannot detect. This response
problem may extend well beyond hepatitis B: the same children
who have not developed an immune response to the HBV vaccine
are also at risk for diphtheria, tetanus, pertussis and Haemophilus
influenzae B.
Current evaluations of vaccination programmes, particularly in
resource-poor countries, necessitate supplemental and regular
biological monitoring, to ensure vaccine quality and storage and to
verify that vaccine recipients are genuinely protected. We would
also call for further studies on larger populations in countries that
participate in the EPI, so as to investigate more fully the vaccines
and their storage and delivery. These results make evidence the
need for collaboration between the Expanded Programme on
Immunization and national programmes to control Hepatitis B.
Such measures should constitute a clear global public health
priority.
Materials and Methods
Study population
This study took place from May 2009 to May 2010, in two
hospitals in Yaounde (Cameroon), the Essos Hospital and the
Chantal Biya Foundation, and in two hospitals in Dakar (Senegal),
the Ho ˆpital Principal and the Albert Royer Paediatric Hospital.
All consecutive children, under 4 years old, hospitalized for any
reason, with a blood sample prescribed during hospitalisation,
sufficiently healthy to withstand an extended blood sample of 2 ml
minimum, with an immunisation card and a complete HBV
vaccination including the three injections according to the
recommended schedule (first dose 6 weeks after birth and intervals
between 2 injections of 30 days minimum) and anti-HBc-negative
were considered in this analysis.
Ethical approvals
Approval to conduct the study was obtained from the National
Ethics Committee and the Ministry of Public Health of Cameroon
and the National Comity of the Research in Health of Senegal. All
children anti-HBs-negative and anti-HBc-negative were invited to
return to receive an HBV vaccination free of charge, no matter the
HBV vaccination status reported on their immunization card.
Data collection
Demographic and socioeconomic characteristics (age, sex,
weight, and reason for hospitalization), vaccination records and
all serological data were collected through a structured question-
naire.
Anthropometric measurements
Malnutrition status was estimated by the weight-for-age Z-score
(WAZ), because most values for the children’s height were missing.
Table 2. Factors associated with HBV vaccine response.
Anti-HBs Univariate analysis Multivariate analysis
Variables ,10 IU/L N=58 $10 IU/L N=184 OR (CI95%) pO R (CI95%) p
Country N( % )
Cameroon 10 (17) 118 (64) 1 1
Senegal 48 (83) 66 (36) 0.1 (0.06–0.2) ,0.001 0.1 (0.06–0.3) ,0.001
Sex, female N (%) 23 (40) 91 (49) 1.5 (0.8–2.7) 0.19
Age #15 months N (%) 17 (29) 108 (59) 3.4 (1.8–6.5) ,0.001 3.1 (1.6–6.1) 0.001
Moderate or severe
malnutrition N( % )
36 (62) 54 (31) 0.3 (0.1–0.5) ,0.001
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Prevention 2000 child growth charts (CDC-2000) [23]. Moderate
or severe malnutrition was defined when the WAZ value was less
or equal to 22.
HBV markers
All samples were tested for anti-HBs and anti-HBc by enzyme
immunoassay (EIA) (DiaSorin Biomedica, Sallugia, Italy). Anti-
HBs antibodies were expressed in international units (IU/L). The
level of anti-HBs of 10 IU/L and higher was considered to be
seroprotective. The responders were defined as children anti-HBs+
and anti-HBc2, while the non responders were defined as
children anti-HBs2 and anti-HBc2.
Diphtheria antibodies
The detection of antibodies against diphtheria was performed
using EIA (IgG testkit, Genzyme, Germany). Levels of anti-
diphtheria antibodies were expressed in international units (IU/
ml). All sera with a level of anti-diphtheria of 0.1 UI/ml and
higher were considered to be positive.
Statistical analysis
Quantitative variables were expressed as median [Q1–Q3] and
qualitative as percentages.
Anti-HBs antibodies were analysed using three categories:
,10 IU/L, 10–99 IU/L, and $100 IU/L. The HBV immune
response was measured taking into account the time of vaccina-
tion, 2006–2007 or 2008–2009, in the two countries. Univariate
analysis was based on the chi2 test or Fisher’s exact test for discrete
variables and the Mann-Whitney test for continuous variables. For
the multivariate analysis, quantitative variables were categorized
around the median. All baseline variables associated with vaccine
response in the univariate analysis (p#0.25) were included in a
backward stepwise logistic regression model. Interactions between
factors associated with vaccine response and participating country
(Senegal and Cameroon) were tested. Results were considered
statistically significant when p,0.05. Correlation between anti-
diphtheria antibody response and anti-HBs antibodies was based
on the Spearman coefficient and linear regression. STATA 11
software was used for all statistical analyses.
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